Elekta (EKTAY) Stock Price, News & Analysis

Company Overview

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Key Stats

• Today's Range: $5.04 to $5.08
• 50-Day Range: $4.76 to $5.19
• 52-Week Range: $4.36 to $7.13
• Volume: 2,848 shs
• Average Volume: 6,190 shs
• Market Capitalization: $1.86 billion
• P/E Ratio: 100.82
• Dividend Yield: 2.38%
• Price Target: N/A
• Consensus Rating: Hold

EKTAY Stock Analysis - Frequently Asked Questions

How have EKTAY shares performed this year?

Elekta's stock was trading at $5.66 at the start of the year. Since then, EKTAY stock has decreased by 11.0% and is now trading at $5.04.

How were Elekta's earnings last quarter?

Elekta AB (OTCMKTS:EKTAY) released its earnings results on Wednesday, May, 28th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by $0.02. The business had revenue of $503.22 million for the quarter, compared to analysts' expectations of $507.19 million. Elekta had a trailing twelve-month return on equity of 11.55% and a net margin of 1.15%.

How do I buy shares of Elekta?

Shares of EKTAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/28/2025
• Today: 8/21/2025
• Next Earnings (Estimated): 8/28/2025
• Fiscal Year End: 4/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:EKTAY
• CIK: 1451160
• Web: www.elekta.com
• Phone: (685) 872-5400
• Fax: 46-8-587-255-00
• Employees: 4,718
• Year Founded: 1972

Profitability

• EPS (Trailing Twelve Months): $0.05
• Trailing P/E Ratio: 100.82
• Forward P/E Ratio: 14.00
• P/E Growth: N/A
• Net Income: $22.37 million
• Net Margins: 1.15%
• Pretax Margin: 2.72%
• Return on Equity: 11.55%
• Return on Assets: 3.75%

Debt

• Debt-to-Equity Ratio: 0.70
• Current Ratio: 1.09
• Quick Ratio: 0.86

Sales & Book Value

• Annual Sales: $1.71 billion
• Price / Sales: 1.09
• Cash Flow: $0.61 per share
• Price / Cash Flow: 8.20
• Book Value: $2.19 per share
• Price / Book: 2.30

Miscellaneous

• Outstanding Shares: 368,590,000
• Free Float: 216,435,000
• Market Cap: $1.86 billion
• Optionable: Not Optionable
• Beta: 1.19